GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
19.60-0.60 (-2.99%)
At close: 11:19 AM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close20.20
Bid0.00 x
Ask0.00 x
Day's Range19.60 - 19.60
52wk Range19.55 - 21.99
1y Target EstN/A
Market Cap100.99B
P/E Ratio (ttm)261.33
Avg Vol (3m)3,103
Dividend & Yield0.94 (4.75%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Forbes12 hours ago

    Does GlaxoSmithKline's Sales Surge Make It An Unmissable 'Buy'?

    GlaxoSmithKline’s latest trading update has smashed broker forecasts. But should you pile in at current share prices?

  • Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View
    Zacks13 hours ago

    Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View

    Glaxo (GSK) reported third-quarter 2016 core earnings of 85 cents per American depositary share, beating the Zacks Consensus Estimate of 77 cents.

  • Reuters15 hours ago

    GSK expands meningitis B vaccine production in Germany

    GlaxoSmithKline said on Thursday it was investing 172 million euros ($188 million) to expand vaccine capacity at its Marburg factory in Germany, with 162 million euros going to increase production of its Bexsero meningitis B shot. The British drugmaker highlighted the vaccine's strong sales performance when it reported results on Wednesday, with sales of the product more than doubling in the third quarter to 133 million pounds ($163 million). The company said it would take a number of years for the new production to come on stream but the investment was a vote of confidence in GSK's vaccines business, which was a bright spot in quarterly results.